Buscar
01/11/2025
Prophylactic Permanent Pacemaker Implantation After Transcatheter Aortic Valve Replacement
Fischer, Q, Nombela-Franco, L, Muntané-Carol, G, Veiga, G, Regueiro, A, Nazif, T, Serra, V, Asmarats, L, Ribeiro, HB, Latib, A, Poulin, A, Cheema, AN, Tirado-Conte, G, Gomez-Hospital, JA, Ongay, AG, Gabani, R, Arzamendi, D, Brener, M, Calabuig, A, Scotti, A, Gelain, MAS, Labinaz, M, Cepas-Guillén, P, Côté, M, del Portillo, JH, Philippon, F, Rodés-Cabau, J. Prophylactic Permanent Pacemaker Implantation After Transcatheter Aortic Valve Replacement. JACC-Clinical Electrophysiology. 2025; 11(11)DOI:10.1016/j.jacep.2025.07.028. PMID:40965381. IF:7.700(Q1/1D).
01/11/2025
Refractory congestion following successful pericardiocentesis for cardiac tamponade: effusive-constrictive pericarditis caused by Cutibacterium acnes
Santaló-Corroy, M, Triguero-Llonch, L, Fernández-Martinez, J, Arias-Pinilla, JP, Ferrer-Menéndez, M, Bonet-Basiero, A. Refractory congestion following successful pericardiocentesis for cardiac tamponade: effusive-constrictive pericarditis caused by Cutibacterium acnes. REVISTA ESPANOLA DE CARDIOLOGIA. 2025; 78(11)DOI:10.1016/j.rec.2025.06.009. PMID:40812677. IF:4.900(Q1/2D).
01/11/2025
Sex differences in mitral regurgitation anatomy and outcomes of transcatheter edge-to-edge repair
Li, CHP, Asmarats, L, van Roessel, AM, Capellades, H, Fernández-Peregrina, E, Arzamendi, D. Sex differences in mitral regurgitation anatomy and outcomes of transcatheter edge-to-edge repair. REVISTA ESPANOLA DE CARDIOLOGIA. 2025; 78(11)DOI:10.1016/j.rec.2025.01.018. PMID:39938677. IF:4.900(Q1/2D).
01/11/2025
Clinicopathological and molecular features of recurrence in ctDNA-negative resected colorectal cancer
Beltran, JS, Pérez, MARSM, Manrique, ACV, Cullell, BM, Munoz, MN, Mateo, FJP, Riera, P, Fuste, V, Fumagalli, C, Szafranska, J, Catasus, L, Gonzalez, A, Paez, D. Clinicopathological and molecular features of recurrence in ctDNA-negative resected colorectal cancer. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.1344. PMID:. IF:65.400(Q1/1D).
01/11/2025
Methotrexate-Induced Gouty Arthritis in Psoriatic Patient
Carmona-Rocha, E, Torné, CD, Alonso, AML, Puig, L. Methotrexate-Induced Gouty Arthritis in Psoriatic Patient. Actas Dermo-Sifiliograficas. 2025; 116(10)DOI:10.1016/j.ad.2024.02.050. PMID:40615030. IF:(Q/D).
01/11/2025
Defining molecular correlates of response using spatial transcriptomics in the SOGUG-AUREA trial
Ballesteros, PA, García-Carbonero, I, Gonzalez, EE, Marin, AP, Lorente, D, de Liaño, AG, Ortega, EM, Colomo, LJ, Puente, J, Gonzalez, I, Calvo, OF, Palacios, GA, Mendizabal, I, Navarro, EP, Domínguez, JID, Esteban-Villarrubia, J, Billalabeitia, EG, Oria, GAD. Defining molecular correlates of response using spatial transcriptomics in the SOGUG-AUREA trial. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.3696. PMID:. IF:65.400(Q1/1D).
01/11/2025
Characterization of locally advanced rectal cancer (LARC) patients (pt) in Spanish TTD-RETUD registry
España, MAG, Calle, SG, Flores, EG, Sosa, MM, Tocino, RV, Plazas, JG, Monteagudo, RF, Aguilera, MJS, Herrero, MDRM, Gargia, TG, Zafra, GM, Arévalo, MA, Orozco, EJ, Manrique, ACV, Alfonso, PG, Montes, AF, Ninerola, RQ, de Castro, EM, Verdaguer, H, García, RV. Characterization of locally advanced rectal cancer (LARC) patients (pt) in Spanish TTD-RETUD registry. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.1362. PMID:. IF:65.400(Q1/1D).
01/11/2025
Exploratory analysis of chromophobe renal cell carcinoma in the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first-line treatment
Ahrens, M, Haanen, JBAG, Albiges, L, Goupil, MG, Boleti, E, Gravis, G, Flechon, A, Grimm, MO, Bedke, J, Barthelemy, P, Gauna, DEC, Gonzalez, BM, Ivanyi, P, Rottey, S, Floercken, A, Rodriguez, CS, Rey, JPM, Burkholder, I, Hartmann, A, Bergmann, L. Exploratory analysis of chromophobe renal cell carcinoma in the SUNNIFORECAST trial comparing Ipilimumab plus Nivolumab vs standard of care as first-line treatment. ANNALS OF ONCOLOGY. 2025; 36DOI:10.1016/j.annonc.2025.08.3211. PMID:. IF:65.400(Q1/1D).